Featured Press Releases

LatigoBio_Logo

"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain

MediPharm Labs launches a new nighttime inhaler, expanding its leading CBN oil portfolio

MediPharm Labs launches a new nighttime inhaler, expanding its leading CBN oil portfolio

  • 30 Jul 2025

MediPharm Labs Corp. a pharmaceutical company specializing in precision-based cannabinoids, is...

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Haleon’s Otrivin® Brand Now Features Aptar’s First Nasal Pump Made with 52% Bio-based Material

Haleon’s Otrivin® Brand Now Features Aptar’s First Nasal Pump Made with 52% Bio-based Material

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

  • Intuitive Ventures
  • 19 Nov 2025
FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

  • Arrowhead Pharmaceuticals, Inc.
  • 19 Nov 2025
Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

  • Emulate, Inc. and FUJIFILM Cellular Dynamics
  • 18 Nov 2025
Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.